Navigation Links
Rutgers neuroscience may hold key to hearing loss remedy

NEW BRUNSWICK, N.J. A Rutgers University team led by neuroscientist Robin Davis is opening new doors to improved hearing for the congenitally or profoundly deaf. Their findings could lead to a new generation of cochlear implants.

Cochlear implants today operate with varying degrees of success in different patients. Some may be able to hear sounds like the rush of traffic or the crash of thunder. Others can do even better, detecting voice and understanding speech while still being unable to appreciate music. With the latest research, across-the-board improvement may be within reach.

Davis work is important for engineers and surgeons in designing new cochlear implants. The significance of our work lies in the fact that we can change an element in a very peripheral part of the sensory system that can have an impact all the way into the brain, Davis said.

Cochlear implants, also known as bionic ears, are surgically inserted into the snail-shell shaped structure the cochlea within the inner ear. Ordinarily, hair cells line the cochlea and convert acoustic signals into electrical signals that nerves then carry to the brain. Where some hair cells exist, sounds can be amplified with a hearing aid. Where the hair cells are missing or damaged a condition generally associated with severe hearing impairment an implant may be used to replace their function.

Davis, a professor in the Department of Cell Biology and Neuroscience of Rutgers School of Arts and Sciences, works with mouse cochlear tissue cultured in the laboratory. The spiraled cochlea is unwound and laid out in a line. Davis described the hair cells as being analogous to the keys of a piano and the nerves to which they attach the spiral ganglion neurons that connect to the brain are the pianos strings.

Our studies have revealed that spiral ganglion auditory neurons possess a rich complexity that is only now beginning to be understood, said Davis.

The researchers found that two neurotrophin proteins in the cochlea brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) figure prominently in the relay of sound messages to the brain. Research by Davis and her team, begun more than six years ago, is now producing insights into precisely how these multidimensional proteins operate in the cochlea. These most recent findings appear in the Dec. 19 issue of The Journal of Neuroscience.

While neurotrophins have historically been prized for the survival value they impart to nerve cells, the researchers found that in the cochlea they do a great deal more. Their presence in relative proportions transforms the spiral ganglion neurons into either fast-firing transmitters to carry high pitched sound messages to the brain, or slow-firing carriers for the transmission of lower pitched signals. The neurotrophins accomplish this at the molecular level by tightly regulating a newly-defined and complex series of signaling proteins.

Davis explained that one end of the cochlea is home to the slower-firing neurons characterized by a preponderance of NT-3, while the other cochlear end is rich in BDNF, making those neurons faster-firing. Both neurotrophins are present in gradients throughout the range, but at any specific locale their amounts vary relative to each other lots of BDNF and a little NT-3 in the high frequency transmitters, for example, and the reverse as you move toward the other end.

In one possible remedial approach, Davis described how the neurotrophins could potentially be pumped into a newly-designed cochlear implant and released through graduated ports along its length.


Contact: Joseph Blumberg
732-932-7084 x652
Rutgers University

Related biology technology :

1. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
4. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
5. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
6. Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
7. Amarin Signs Agreement to Acquire Ester Neurosciences
8. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
9. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
Post Your Comments:
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions to ... symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory science, ...
(Date:10/9/2017)... ... 2017 , ... The Giving Tree Wellness Center announces the ... of consumers who are incorporating medical marijuana into their wellness and health regimens. ... operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach Mazor ...
(Date:10/7/2017)... Oct. 6, 2017  The 2017 Nobel Prize ... scientists, Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to ... structural biology community. The winners worked with systems ... routinely produce highly resolved, three-dimensional images of protein ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):